Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis

被引：0

作者：

Antoni, C ^{[1
]}

Kalden, JR ^{[1
]}

机构：

[1] Univ Erlangen Nurnberg, Inst Immunol & Rheumatol, Dept Med 3, D-91023 Erlangen, Germany

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 1999年 / 17卷 / 06期

关键词：

infliximab; methotrexate; tumor necrosis factor; combination treatment; rheumatoid arthritis; efficacy; side effects; immunogenecity;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Infliximab, a chimeric anti-TNF alpha antibody, showed in two double-blind placebo-controlled trials efficacy in combination with methotrexate (MTX) inpatients with severe rheumatoid arthritis (RA). Whereas in the first trial low-dose MIX or placebo was compared to infliximab alone and in combination, the second trial compared infliximab to placebo inpatients with active RA despite maximal tolerated MTX treatment. Infliximab showed synergistic effects in combination with MTX. The immunogenicity of infliximab was reduced by the combination. Infliximab in combination with high-dose MTX is effective and safe in long-term treatment up to 54 weeks.

引用

页码：S73 / S77

页数：5

共 50 条

[41] Obesity and Remission Rates in Japanese Patients With Rheumatoid Arthritis Requiring Anti-Tumor Necrosis Factor Alpha Therapy [J].

Yamazaki, Kenji ;

Suzuki, Etsuji ;

Ishihara, Ryuhei ;

Miyamoto, Toshiaki .

ARCHIVES OF RHEUMATOLOGY, 2020, 35 (04) :600-608

[42] Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis [J].

Gia Deyab ;

Ingrid Hokstad ;

Jon Elling Whist ;

Milada Cvancarova Smastuen ;

Stefan Agewall ;

Torstein Lyberg ;

Nicoletta Ronda ;

Knut Mikkelsen ;

Gunnbjorg Hjeltnes ;

Ivana Hollan .

Arthritis Research & Therapy, 19

[43] Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis [J].

Kageyama, Yasunori ;

Torikai, Eiji ;

Nagano, Akira .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (05) :467-472

[44] Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis [J].

Yasunori Kageyama ;

Eiji Torikai ;

Akira Nagano .

Rheumatology International, 2007, 27 :467-472

[45] Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy [J].

Julia, Antonio ;

Lopez-Lasanta, Maria ;

Blanco, Francisco ;

Gomez, Antonio ;

Haro, Isabel ;

Mas, Antonio Juan ;

Erra, Alba ;

Vivar, Ma Luz Garcia ;

Monfort, Jordi ;

Sanchez-Fernandez, Simon ;

Gonzalez, Isidoro ;

Alperi, Mercedes ;

Castellanos-Moreira, Raul ;

Fernandez-Nebro, Antonio ;

Diaz-Torne, Cesar ;

Palau, Nuria ;

Lastra, Raquel ;

Llados, Jordi ;

Sanmarti, Raimon ;

Marsal, Sara .

BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)

[46] Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy [J].

Antonio Julià ;

María López-Lasanta ;

Francisco Blanco ;

Antonio Gómez ;

Isabel Haro ;

Antonio Juan Mas ;

Alba Erra ;

Ma Luz García Vivar ;

Jordi Monfort ;

Simón Sánchez-Fernández ;

Isidoro González ;

Mercedes Alperi ;

Raúl Castellanos-Moreira ;

Antonio Fernández-Nebro ;

César Díaz-Torné ;

Núria Palau ;

Raquel Lastra ;

Jordi Lladós ;

Raimon Sanmartí ;

Sara Marsal .

BMC Musculoskeletal Disorders, 22

[47] Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis:: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) [J].

Furst, DE ;

Schiff, MH ;

Fleischmann, RM ;

Strand, V ;

Birbara, CA ;

Compagnone, D ;

Fischkoff, SA ;

Chartash, EK .

JOURNAL OF RHEUMATOLOGY, 2003, 30 (12) :2563-2571

[48] Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α [J].

Onishi, Sachiko ;

Yoshio, Taku ;

Nagashima, Takao ;

Minota, Seiji .

MODERN RHEUMATOLOGY, 2010, 20 (05) :528-530

[49] Suboptimal clinical response to anti-tumor necrosis factor alpha (TNFα) antibody therapy in a patient with severe rheumatoid arthritis and lymphadenopathy [J].

Saeki, Y ;

Ohshima, S ;

Mima, T ;

Sasai, M ;

Nishioka, K ;

Shimizu, M ;

Suemura, M ;

McCloskey, R ;

Kishimoto, T .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1998, 27 (04) :303-305

[50] Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis [J].

Che, Helene ;

Lukas, Cedric ;

Morel, Jacques ;

Combe, Bernard .

JOINT BONE SPINE, 2014, 81 (03) :215-221

← 1 2 3 4 5 →